TKIs targeting VEGFR, such as sorafenib, sunitinib, and lenvatinib, have been explored in clinical trials for ovarian cancer, primarily aiming to inhibit tumor angiogenesis (125). The gene discussed is KDR; the disease is ovarian cancer.